Introduction:

Beximco Pharmaceuticals Ltd. is the leading pharmaceutical company of Bangladesh. Founded in

1976, Beximco Pharmaceuticals Ltd. has been producing world class pharmaceutical products
following current Good Manufacturing Practice (CGMP) as required by the World Health
Organization (WHO) in order to improve health, happiness and quality of life. Beximco
Pharmaceuticals Ltd. has products of different therapeutic classes, each of which occupies a
prominent position in the market and the heart of our customers and shareholders.

Beximco Pharmaceuticals Ltd. is always committed to improve the lives of people through the
development and commercialization of high quality and cost-effective medicines.

SWOT ANALYSIS

Strength:

Diversification:

The strength of Beximco Pharmaceuticals Ltd. lies in its diversified products and dosage forms.BPL
has been producing solid products like tablets and capsules and liquid products like syrup, suspension
and solution, as well as semisolid products like cream and ointment.  It is the pioneer company to
manufacture and market nasal sprays, inhalation aerosols and suppositories in Bangladesh. In 2001,
Beximco Pharmaceuticals Ltd. stepped into a new path--bringing Small Volume Parenteral (SVP) or
inject able dosage form. Arixon is it’s first small volume inject able product It is a preparation of
Ceftriaxone, which is considered as a breakthrough antibiotic in the history of medicine, . In 2002,
Arixon is predicted to be one of our leading brands interms of sales revenue. The company has lot of
diversified products like, Napa: Neoceptin R: Neofloxin: Tycil : Aristovit M etc.

Achievement of national export trophy:

First export market operation with finished pharmaceutical products1994-95 : Achievement of

National Export Trophy (Gold) as the first pharmaceutical company of the country.

R & D:

B P L is a company that is continuously searching for the next treatment advancements. BPL’s
portfolio features a range of high-quality, effective products. This product portfolio, combined with
the steady stream of promising new products in development, is one of the many reasons BPL is
among the nation'sI leading pharmaceutical companies. We have introduced 26 new products in 2001.
Around 70 new products are in our development pipeline. They will obviously enrich our portfolio
toeloypment of the employees so that they can cope with the rapidly changing business environment.
Innovation is a major priority that we want to promote. Accordingly, training programs are regularly
undertaken for the staff to seek opportunities for skills improvement.
Weakness:

 Insufficient working capital.

 Net operating in low cost market.

Opportunities:

BPL always tried to add new products of different therapeutic classes in its portfolio and these
products are highly appreciated by the health professionals. Most important of them are Triocim,
Arixon, Prosan, Recox, Atova etc.Introduction of these new products enriched it’s product portfolio
and is contributing to enhance it’s sales.Apart from all these, we have intensifiedand consolidated our
marketing efforts inother overseas markets, like Myanmar, Kenya, Yemen and Vietnam. To capitalize
immense opportunities in these overseas markets, we are bringing in more new andexciting brands in
these markets. Last year, BPL donated one ‘Medical Information i o s k ’ to the Myanmar Medical
Association of Mandalay which gained enormous attention and acceptance in the minds of the
medical community of Myanmar. In Kenya, number of salespeople has been increased to best exploit
its huge market potentials. All these efforts are already bringing in desired results. Entering into new
horizons and establishing new overseas markets will remain our top most priority in 2002 also.
Russia, Ukraine, Sri Lanka, Cambodia, Nepal will be on the list. We are confident that our process of
globalization will continue with a more and more accelerated speed in the coming days.

Technology

Keeping pace with the advanced world Technology carries the promise of tomorrow. The benefits of
technology belong to all of us benefits that create new opportunities and open doors to a better life.
For example, the new inhaler plant of BPL has been designed in a way to ensure highest-possible
quality at every stage of manufacturing and quality control. World-class facilities are being employed
in each and every step including mixing, filling, testing, labeling, batch printing and other procedures
to ensure manufacturing of world class products.

Threats:

BPL has a commitment to the society to supply world class Active Pharmaceutical Ingredients (APIs).
Therefore, BPL is not only engaged in formulations but also in fine chemicals business with a view to
supplying cost effective quality materials to other local companies as well as for captive consumption.

Beximco Pharmaceuticals Ltd. has been preparing itself for the post-WTO open market competition.
It has all the courage to compete with world leaders in pharmaceuticals business when the tariff and
non-tariff barriers will be withdrawn the new USFDA standard plant is planned to be operational in
early 2003. Once completed, this will be one of the finest facilities to be available anywhere in the
globe.
Strategies
Beximco Pharma has adopted several Corporate Level Strategies regarding growth and market focus
based on the SWOT analysis with the view to achieving organizational goals. As Growth
Strategy BPL have decided to enter into nine new international markets in Asia, Middle East,
Pacific Islands, Africa and Central America and have registered 107 products in different
markets. Besides, BPL signed a Long Term Arrangement with the Global Supply Division of
UNICEF (Denmark) to supply 60,000 units CFC free metered dose inhaler product over a two year
contract period. During the first quarter of 2008, BPL has entered into 3 new international
markets- namely, Afghanistan, Kiribati and Solomon Islands. Their Short Term plan to build
facility to manufacture Small Volume Parenterals (SVP), Opthalmic and Nebulizer Solutions
has progressed as scheduled. They are planning to commence marketing of these products by first
quarter of 2009.

Competitive Advantage:
Business level strategies developed by BPL help them to earn competitive advantage through
quality products, superior services, and outstanding customer relationship. Innovation strategies
have been the key to their success both in product differentiation and in product promotion. BPL had
been the first-mover to bring Marketing Approach rather than traditional Selling Approach in local
pharmaceuticals industry. BPL also believes in Focus Strategy and concentrates on a particular
segment of the market. They strive to retain existing customers as well as to attract new ones.
BPL has developed unique customer service through their Unbiased Medical Service. BPL has also
developed superior human resource for earning competitive advantage in the market.

Business strategy:

As we know, pharmaceuticals business in Bangladesh, as in the world, is highly competitive.

In the post-WTO regime, it is going to be further intensely competitive. This is particularly
true for the developing and least developed countries. I am pleased to announce that your
company is quite mindful of the challenges ahead and confident of its capabilities to face
them. While reinforcing our base to survive competition, we at the same time are putting our
best effort to take advantage of the potential avenues that the new global economic order is
going to bring about. As in the past, retaining and expanding the domestic market share will
continue to be the main focus of our marketing strategy. Our investment for new product and
increased market share will continue to consolidate the base. We plan to further strengthen
the basic chemicals portfolio. Increased focus will also be on R & D activities to develop new
products and dosage forms. Alongside with growing in the domestic market, BPL will
aggressively pursue to secure significant growth in export sales. In this direction, our strategy
is to expand the already explored international markets and further intensify our search for
potential new geographic locations.